You are here
AMT, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
ENDOSCOPIC LIGHT SOURCE FOR PDT
Amount: $278,132.00DESCRIPTION (Verbatim from the Applicant's Abstract): We propose to continue to develop and test a self-contained light delivery device for use in photodynamic therapy (PDT) for Barrett's es ...
STTRPhase II2001Department of Health and Human Services National Institutes of Health -
ENDOSCOPIC LIGHT SOURCE FOR PDT
Amount: $0.00DESCRIPTION (Verbatim from the Applicant's Abstract): We propose to continue to develop and test a self-contained light delivery device for use in photodynamic therapy (PDT) for Barrett's es ...
STTRPhase I2001Department of Health and Human Services National Institutes of Health -
N/A
Amount: $100,000.00N/A
SBIRPhase I2000Department of Health and Human Services National Institutes of Health -
THERMODILUTION RIGHT VENTRICULAR EJECTION FRACTION
Amount: $100,000.00N/A
STTRPhase I1999Department of Health and Human Services -
MICROWAVE AIDED LIPOSUCTION
Amount: $100,000.00N/A
SBIRPhase I1998Department of Health and Human Services -
POLYMERIC DELIVERY SYSTEMS FOR ANTIRETROVIRAL AGENTS
Amount: $49,855.00THE GOAL OF THIS PHASE I RESEARCH IS TO DESIGN, SYNTHESIZE, DEVELOP, AND EVALUATE THE IN VITRO EFFICACY OF A NEW CLASS OF POLYMERIC "TARGETED" PRODRUGS OF AZT. THE OVERALL OBJECTIVE OF THIS PROGRAM IS ...
SBIRPhase I1990Department of Health and Human Services -
SOLUBILIZATION AND SUSTAINED DELIVERY OF ANTITUMOR AGENTS
Amount: $49,838.00THE OVERALL OBJECTIVE IS TO PROVIDE A NEW DRUG DELIVERY SYSTEM AND TO ENHANCE THE SOLUBILITY OF EXISTING COMPOUNDS THAT EXHIBIT EXCELLENT ANTITUMOR PROPERTIES BUT ARE INSOLUBLE IN WATER. AQUEOUS SOLUB ...
SBIRPhase I1990Department of Health and Human Services -
NEW TARGET-DIRECTED PT-PORPHYRIN ANTICANCER DRUGS
Amount: $46,000.00THE OBJECTIVE OF THIS PROJECT IS TO IMPROVE THE SELECTIVITY OF ACTION OF PLATINUM ANTITUMOR AGENTS. PLATINUM COMPOUNDS HAVE SHOWN ACTIVITY IN MANY TYPES OF TUMORS, BUT SEVERE DOSE-LIMITING SIDE EFFECT ...
SBIRPhase I1987Department of Health and Human Services -
MECHANISM-BASED ELASTASE INHIBITORS
Amount: $50,000.00SYNTHETIC ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF EMPHYSEMA WILL BE DEVELOPED. IN PHASE I, NEW MECHANISM-BASED ELASTASE INHIBITORS WILL BE SYNTHESIZED, CHARACTERIZED, AND STUDIED AS INHIBITORS ...
SBIRPhase I1987Department of Health and Human Services -
THE COMPLEX 4-CARBOXYPHTHALATO (1, 2-DIAMINOCYCLOHEXANE) PLATINUM (NSC 271674; DACH-PT) HAS UNDERGONE LIMITED CLINICAL TRIALS.
Amount: $50,000.00THE COMPLEX 4-CARBOXYPHTHALATO (1, 2-DIAMINOCYCLOHEXANE) PLATINUM (NSC 271674; DACH-PT) HAS UNDERGONE LIMITED CLINICAL TRIALS. DESIGNED AS AN ALTERNATIVE THERAPY TO CISPLATIN, IT HAS DEMONSTRATED SUBS ...
SBIRPhase I1986Department of Health and Human Services